- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT04209725
A Study of CPX-351 (Vyxeos™) With Quizartinib for the Treatment of FLT3-ITD Mutation-Positive Acute Myeloid Leukemia
A Phase II Study Assessing CPX-351 (Vyxeos™) With Quizartinib for the Treatment of Relapsed or Refractory FLT3-ITD Mutation-Positive AML
This is a research study to be done at multiple sites in participants with advanced acute myeloid leukemia (AML) that have a mutation in Fms-like tyrosine kinase-3 internal tandem duplications (FLT3-ITD). This study is to learn more about an investigational drug, quizartinib, being tested with the anti-cancer medicine CPX-351 (also called Vyxeos™), which is approved and widely used to treat AML.
The purpose of this study is to assess the safety, tolerability and survival of patients receiving the combination of CPX-351 and quizartinib.
Study Overview
Status
Conditions
Intervention / Treatment
Detailed Description
Study Type
Enrollment (Actual)
Phase
- Phase 2
Contacts and Locations
Study Locations
-
-
Colorado
-
Denver, Colorado, United States, 80218
- Colorado Blood Cancer Institute
-
-
Missouri
-
Kansas City, Missouri, United States, 64132
- HCA Midwest
-
-
Tennessee
-
Nashville, Tennessee, United States, 37203
- Tennessee Oncology
-
-
Texas
-
Austin, Texas, United States, 78704
- St. David's South Austin Medical Center
-
San Antonio, Texas, United States, 78229
- Texas Transplant Institute
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Description
Inclusion Criteria:
- Written informed consent form (ICF), according to local guidelines, signed by the patient or by a legal guardian prior to the performance of any study-related screening procedures.
Patients with the following types of AML with >5% blasts:
- Relapsed FLT3-ITD mutation-positive AML, diagnosed by bone marrow (BM) biopsy with FLT3 mutation by polymerase chain reaction (PCR)
- Refractory FLT3-ITD mutation-positive AML, diagnosed by BM biopsy with FLT3 mutation by PCR
- Relapsed or refractory FLT3-ITD mutation-positive AML after HCT, diagnosed by BM biopsy with FLT3 mutation by PCR
- Relapsed or refractory AML with de novo FLT3-ITD mutation, diagnosed by BM biopsy with FLT3 mutation by PCR
- Relapsed or refractory AML after HCT with de novo FLT3-ITD mutation, diagnosed by BM biopsy with FLT3 mutation by PCR
- First-line therapy must have contained a standard induction chemotherapy (e.g. 7+3, FLAG-IDA, FLAG, CLAG, MEC, hypomethylating agent with venetoclax) with or without receiving a prior FLT3 inhibitor (e.g. midostaurin) or multi-tyrosine kinase inhibitor (e.g. sorafenib). All patients who relapsed after an alloHCT are included, except patients with active graft-versus-host disease (GVHD) requiring >10 mg prednisone.
- Patients must be able to swallow and retain oral medication.
- Eastern Cooperative Oncology Group (ECOG) Performance Status score of 0, 1, or 2 (Appendix A).
- Adequate renal and hepatic parameters (aspartate aminotransferase [AST], alanine aminotransferase [ALT] ≤2.5 institutional upper limit of normal [ULN]; total bilirubin ≤2.0 institutional ULN; serum creatinine [Cr] ≤2.0). In patients with suspected liver infiltration, ALT can be ≤5 institutional ULN.
Exclusion Criteria:
- Acute promyelocytic leukemia (t[15;17])
- Female patients who are lactating or have a positive serum pregnancy test during the screening period. Female patients of childbearing potential who are not willing to employ highly effective birth control (as defined in Appendix C of protocol) from screening to 6 months following the last dose of CPX-351 and/or quizartinib.
Evidence of active and uncontrolled bacterial, fungal, parasitic, or viral infection. Infections are considered controlled if appropriate therapy has been instituted and, at the time of screening, no signs of active infection progression are present. This is assessed by the site clinicians, including an infectious disease consulting physician, if requested by the Principal Investigator (PI), regarding adequacy of therapy. These infections include, but are not limited to:
- Known human immunodeficiency virus (HIV) infection
- Active hepatitis B or C infection with rising transaminase values
- Active tuberculosis infection
- History of hypersensitivity to cytarabine, daunorubicin, or an FLT3 inhibitor
- Any patients with known significant impairment in gastrointestinal (GI) function or GI disease that my significantly alter the absorption of quizartinib.
- Psychological, familial, sociological, or geographical conditions that do not permit compliance with the protocol.
Uncontrolled or significant cardiovascular disease, including any of the following:
- Bradycardia of less than 50 beats per minute, unless the patient has a pacemaker
- QTcF interval using Fridericia's correction factor (QTcF) interval prolongation, defined as >450msec at screening and prior to first administration of quizartinib
- Diagnosis of or suspicion of long QT syndrome (including family history of long QT syndrome)
- Systolic blood pressure ≥180 mmHg or diastolic blood pressure ≥110 mmHg
- History of clinically relevant ventricular arrhythmias (i.e., ventricular tachycardia, ventricular fibrillation or Torsades de pointes)
- History of second or third degree heart block without a pacemaker
- Right bundle branch and left anterior hemiblock (bifascicular block), complete left bundle branch block
- Ejection fraction <50% by transthoracic echocardiogram (TTE) or multigated acquisition (MUGA) scan
- History of uncontrolled angina pectoris or myocardial infarction within 6 months prior to Screening
- History of New York Heart Association Class 3 or 4 heart failure
- Prior anthracycline (or equivalent) cumulative exposure ≥368 mg/m2 daunorubicin (or equivalent)
- Any serious underlying medical condition that, in the opinion of the Investigator or Medical Monitor, would impair the ability to receive or tolerate the planned treatment.
- Patients with inadequate adequate pulmonary function will be excluded. Inadequate pulmonary function is defined as requiring supplemental O2, or diffusing capacity of the lungs for carbon monoxide [DLCO] <40%.
- Active acute or chronic GVHD requiring prednisone >10 mg or equivalent.
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: N/A
- Interventional Model: Single Group Assignment
- Masking: None (Open Label)
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Experimental: CPX-351 and Quizartinib treatment
Participants with FLT3 mutation positive AML will be given CPX-351 followed by quizartinib in three phases: induction, consolidation, and maintenance.
|
Given during the induction and consildation phase and will consist of 44 mg/m^2 daunorubicin with 100 mg/m^2 cytarabine administered intravenously on Days 1, 3, and 5 during induction phase and Days 1 and 3 of consolidation phase.
Other Names:
Given during induction, consolidation, and maintenance phases and will be taken orally at a dose of 30mg on Days 8-21 of induction phase, Days 6-21 of consolidation phase, and daily in maintenance phase.
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Number of Patients With Treatment Related Adverse Events After Taking CPX-351 and Quizartinib
Time Frame: Collected during treatment and for 30 days after last dose, approximately 35 total days for the 1 patient treated.
|
Counting the number of patients with treatment related adverse events as a measure of safety and tolerability.
|
Collected during treatment and for 30 days after last dose, approximately 35 total days for the 1 patient treated.
|
Number of Patients With an Overall Response Taking CPX-351 and Quizartinib
Time Frame: from cycle 1 day 1 (each cycle is 28 days) until disease progression for up to 2 years post treatment
|
Overall response is defined by the International Working Group response criteria (Cheson et al 2003) as having a complete remission (CR) - a complete morphologic response with complete blood count recovery absolute neutrophil count ≥1000/μL and platelet count ≥100,000/μL) or a complete morphologic response with an incomplete blood count recovery (CRi) - absolute neutrophil count <1000/μL and/or platelet count <100,000/μL)
|
from cycle 1 day 1 (each cycle is 28 days) until disease progression for up to 2 years post treatment
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Median Time to Platelet Count Recovery
Time Frame: from cycle 1 Day 1 (each cycle is 28 days) for up to 24 months
|
Time to platelet recovery is defined as the time to when the peripheral blood platelet count is >50, 000/ μL
|
from cycle 1 Day 1 (each cycle is 28 days) for up to 24 months
|
Median Time to Absolute Neutrophil Count (ANC) Recovery
Time Frame: from Cycle 1 Day 1 (each cycle is 28 days) for up to 24 months
|
Time to neutrophil recovery is defined as the time to when the peripheral blood ANC is ≥500/μL
|
from Cycle 1 Day 1 (each cycle is 28 days) for up to 24 months
|
Number of Patients Proceeding to an Allogeneic Hematopoietic Cell Transplantation (alloHCT)
Time Frame: up to 60 days after consolidation therapy
|
Patients receiving allogeneic hematopoietic cell transplantation (alloHCT) following treatment in induction and consolidation therapies.
|
up to 60 days after consolidation therapy
|
Median Time to Disease Progression
Time Frame: from diagnosis of relapse or refractory AML until disease progression for up to 2 years post treatment
|
Time to disease progression, confirmed by bone marrow biopsy.
|
from diagnosis of relapse or refractory AML until disease progression for up to 2 years post treatment
|
Event-free Survival Time
Time Frame: from day 1 for up to 4 years
|
Defined as the number of days until evidence of PD by bone marrow biopsy/aspirate, or death, regardless of cause.
Patients who are alive without a disease response assessment of relapsed disease will be censored at the last adequate disease assessment date.
Patients without a disease response assessment will be censored at the first date of treatment.
|
from day 1 for up to 4 years
|
Overall Survival (OS)
Time Frame: Up to 8 months
|
Overall survival is defined as the time from the first date of treatment until death as a result of any cause.
For OS time, patients that have not died or are lost to follow-up will be censored at the date the patient was last known to be alive or the date of last contact.
|
Up to 8 months
|
Number of Patients Who Develop Late Responses
Time Frame: up to 4 years
|
Late responses as defined by the International Working Group response criteria (Cheson et al 2003) as having a complete remission (CR) - a complete morphologic response with complete blood count recovery absolute neutrophil count ≥1000/μL and platelet count ≥100,000/μL) or a complete morphologic response with an incomplete blood count recovery (CRi) - absolute neutrophil count <1000/μL and/or platelet count <100,000/μL
|
up to 4 years
|
Number of Patients Who Can Receive Consolidation and Maintenance Therapy
Time Frame: approximately 3 months
|
Patients who proceed through induction to next stages of consolidation and maintenance
|
approximately 3 months
|
Treatment-related Mortality Rate
Time Frame: Observed during treatment and for 30 days after last dose, so approximately 35 days for the 1 patient treated.
|
As determined by the number of treatment related deaths during study treatment
|
Observed during treatment and for 30 days after last dose, so approximately 35 days for the 1 patient treated.
|
Percentage of Patients Who Achieve a PR or Molecular Complete Remission
Time Frame: from cycle 1 day 1 (each cycle is 28 days) until disease progression for up to 2 years post treatment
|
A PR is defined as persistent disease by morphology but with a >50% reduction in the blast count/cellularity ratio compared to the most recent BM biopsy prior to treatment.
A molecular complete remission is defined as no evidence of disease by bone marrow biopsy/aspirate by morphology, immunohistochemistry, or flow cytometry, and FLT3 mutation by MRD analysis.
|
from cycle 1 day 1 (each cycle is 28 days) until disease progression for up to 2 years post treatment
|
Mean Elapsed Time for Patients to Achieve Molecular CR
Time Frame: From Date of First Treatment to up to 2 years
|
The mean time to achievement of a complete morphologic CR with persistent disease detected by flow or molecular minimal residual disease (MRD) analysis.
|
From Date of First Treatment to up to 2 years
|
Quizartinib Tolerability After Allogeneic Hematopoietic Cell Transplantation (alloHCT) or Donor Lymphocyte Infusion (DLI)
Time Frame: From Date of First Treatment, up to 2 years
|
Defined as the number of patients who received quizartinib and proceeded to alloHCT or DLI as part of this study and had treatment-related adverse events
|
From Date of First Treatment, up to 2 years
|
Collaborators and Investigators
Investigators
- Study Chair: Michael Tees, MD, MPH, Colorado Blood Cancer Institute
Study record dates
Study Major Dates
Study Start (Actual)
Primary Completion (Actual)
Study Completion (Actual)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Actual)
Study Record Updates
Last Update Posted (Estimated)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Keywords
Additional Relevant MeSH Terms
Other Study ID Numbers
- SCRI AML 48
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Leukemia, Myeloid, Acute
-
University of PennsylvaniaActive, not recruitingAcute Myeloid Leukemia, in Relapse | Acute Myeloid Leukemia, Refractory | Acute Myeloid Leukemia, PediatricUnited States
-
Terrence J Bradley, MDImago BioSciences, Inc., a subsidiary of Merck & Co., Inc., (Rahway, New...RecruitingAcute Myeloid Leukemia | Refractory Acute Myeloid Leukemia | Acute Myeloid Leukemia, in RelapseUnited States
-
Bhavana BhatnagarCTI BioPharmaCompletedRecurrent Adult Acute Myeloid Leukemia | Secondary Acute Myeloid Leukemia | Untreated Adult Acute Myeloid Leukemia | Therapy-Related Acute Myeloid LeukemiaUnited States
-
National Cancer Institute (NCI)RecruitingAcute Myeloid Leukemia | Secondary Acute Myeloid Leukemia | Recurrent Acute Myeloid Leukemia | Refractory Acute Myeloid LeukemiaUnited States
-
Washington University School of MedicineWithdrawnRefractory Acute Myeloid Leukemia | Relapsed Acute Myeloid LeukemiaUnited States
-
C. Babis AndreadisGateway for Cancer Research; AVEO Pharmaceuticals, Inc.TerminatedAcute Myeloid Leukemia | Refractory Acute Myeloid Leukemia | Relapsed Acute Myeloid LeukemiaUnited States
-
City of Hope Medical CenterNational Cancer Institute (NCI)RecruitingAcute Myeloid Leukemia | Recurrent Adult Acute Myeloid Leukemia | Secondary Acute Myeloid Leukemia | Refractory Acute Myeloid LeukemiaUnited States
-
Kronos BioActive, not recruitingAcute Myeloid Leukemia | Refractory Acute Myeloid Leukemia | Relapsed Acute Myeloid LeukemiaUnited States, Spain
-
Massachusetts General HospitalExelixisCompletedRefractory Acute Myeloid Leukemia | Relapsed Acute Myeloid LeukemiaUnited States
-
City of Hope Medical CenterNational Cancer Institute (NCI)Active, not recruitingAcute Myeloid Leukemia | Secondary Acute Myeloid Leukemia | Untreated Adult Acute Myeloid Leukemia | Recurrent Acute Myeloid Leukemia | Refractory Acute Myeloid Leukemia | Therapy-Related Acute Myeloid LeukemiaUnited States
Clinical Trials on CPX-351
-
French Innovative Leukemia OrganisationAcute Leukemia French Association; French Intergroup of Myeloproliferative...RecruitingAcute Myeloid Leukemia | Myeloproliferative SyndromeFrance
-
Case Comprehensive Cancer CenterActive, not recruitingMyelodysplastic Syndromes | Refractory Acute Myeloid Leukemia | Relapsed Acute Myelomonocytic LeukemiaUnited States
-
Jazz PharmaceuticalsIqvia Pty LtdCompleted
-
Groupe Francophone des MyelodysplasiesCompleted
-
Jazz PharmaceuticalsCompletedTherapy-Related Acute Myeloid Leukemia | Acute Myeloid Leukemia With Myelodysplasia-Related ChangesUnited States
-
Jazz PharmaceuticalsAdvice Pharma S.r.l.RecruitingAcute Myeloid Leukemia (AML) | Therapy-Related Acute Myeloid Leukemia | Acute Myeloid Leukemia With Myelodysplasia-Related ChangesItaly
-
Yale UniversityWithdrawn
-
Jazz PharmaceuticalsCompletedAcute Myeloid Leukemia | Myelodysplastic Syndromes | Acute Lymphoblastic Leukemia | Acute Lymphocytic Leukemia | Hematologic MalignancyUnited States, Canada
-
Weill Medical College of Cornell UniversityJazz PharmaceuticalsCompletedMyelodysplastic Syndrome | Acute Myelogenous LeukemiaUnited States
-
Jazz PharmaceuticalsCompletedAcute Myeloid Leukemia (AML) | Acute Lymphoblastic Leukemia (ALL) | Myelodysplastic Syndrome (MDS)United States